Daptomycin
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Daptomycin: From Gram-Positive Bacterial Infections to Osteoarthritis
One-Sentence Summary
Daptomycin is a cyclic lipopeptide antibiotic registered in Singapore as an injectable product, and it is known to be used against Gram-positive bacterial infections. The TxGNN model predicts it may be effective for osteoarthritis, but the data compiled for this report show 0 clinical trials and 10 publications, and none of those publications supports treating non-infectious osteoarthritis. The high score most likely reflects the drug's use in bone and joint infections, not a real therapeutic link.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore licence records (the approved-indication text is empty for all 7 licences). The drug is generally known as an antibacterial for Gram-positive infections. |
| Predicted New Indication | Osteoarthritis |
| TxGNN Prediction Score | 99.86% |
| Evidence Level | L4 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 7 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Daptomycin is a cyclic lipopeptide antibiotic with activity against Gram-positive bacteria. Published work cited here describes its use in osteoarticular and prosthetic joint infections caused by organisms such as Staphylococcus.
For osteoarthritis, no mechanistic link has been established. The publications retrieved concern infection of bones and joints, which is a different disease from degenerative osteoarthritis. The high TxGNN score probably reflects closeness in the knowledge graph between the drug's bone/joint infection use and the joint-disease term, not evidence of benefit in osteoarthritis.
Of the other predictions, rheumatoid arthritis has the only plausible mechanistic signal. A 2025 animal study (PMID 39571268) reported that daptomycin reduced collagen-induced arthritis by suppressing inflammatory cytokines and the NF-κB pathway. This is preclinical only and is a research question, not a basis for clinical use. The predictions ranked 5 to 10 are rare genetic skeletal or developmental syndromes with no data and no plausible mechanism.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Ten publications were retrieved for osteoarthritis. All concern bone and joint infection, not degenerative osteoarthritis.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 23519823 | 2013 | Cohort | International Orthopaedics | Safety and efficacy of high-dose daptomycin plus rifampicin in Gram-positive osteoarticular infections |
| 17999973 | 2008 | Cohort | J Antimicrob Chemother | Outcomes of daptomycin versus standard therapy in osteoarticular infections with S. aureus bacteraemia |
| 22511636 | 2012 | Cohort | J Antimicrob Chemother | Clinical efficacy and safety of daptomycin in knee and hip periprosthetic joint infections |
| 26235888 | 2015 | Cohort | Int J Antimicrob Agents | High-dose daptomycin (>6 mg/kg) in complicated bone, joint and implant-associated infections |
| 21477701 | 2010 | Cohort | Medicina Clínica | Spanish experience with daptomycin from the EU-CORE registry |
| 25650692 | 2015 | Cohort | Surgical Infections | Ten-year evolution of staphylococci isolated from osteoarticular infections |
| 23312602 | 2013 | Survey | Int J Antimicrob Agents | Survey of current practice in managing prosthetic joint infection |
| 22854340 | 2012 | In vitro | J Antibiot | Antibiotic susceptibility of staphylococci from prosthetic joint infections |
| 32206362 | 2020 | Case report | Case Reports in Orthopedics | Chronic Corynebacterium striatum septic arthritis in a patient with osteoarthritis referred for knee replacement |
| 41853106 | 2026 | Case report | ASM Case Reports | Septic arthritis due to Corynebacterium propinquum in a native joint |
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN16443P | Pfizer Daptomycin 500 mg/vial | Lyophilised powder for injection/infusion | Not stated in the records |
| SIN16813P | Penmix Daptomycin 500 mg/vial | Lyophilised powder for injection/infusion | Not stated in the records |
| SIN16828P | Bedapt Daptomycin 500 mg/vial | Powder for solution for injection/infusion | Not stated in the records |
| SIN17204P | Daptomycin/Anfarm 500 mg/vial | Lyophilised powder for injection/infusion | Not stated in the records |
| SIN16900P | Daptomycin-AFT 500 mg/vial | Lyophilised powder for injection/infusion | Not stated in the records |
Two further licences are valid: SIN16071P (Daptoccord 500) and SIN13501P (Cubicin 500 mg). In total there are 7 valid single-ingredient licences, all injectable.
Safety Considerations
Package insert warnings and contraindications were not available for this report. Please refer to the package insert for safety information.
- Disease-level contraindication signals (knowledge graph, not label text): myopathy and other muscle diseases, familial periodic paralysis, diarrhoeal disease including Clostridium difficile colitis, perinatal necrotising enterocolitis, eosinophilic pneumonia and pulmonary eosinophilia, and peripheral neuropathy. These are signals from a knowledge graph and need to be checked against the label.
- Muscle toxicity: a published case (PMID 36693494) describes daptomycin-induced rhabdomyolysis followed by acute gouty arthritis. This points to potential harm, not benefit, in gout.
- Drug interactions (12 found):
- Moderate: rosuvastatin, simvastatin, ibuprofen, diclofenac, celecoxib, ethinylestradiol, cyclosporine, mycophenolic acid, picosulfuric acid, iobenguane (I-131)
- Minor: warfarin, dicoumarol
The statin interactions are worth attention given the muscle toxicity signal. NSAID co-use is also relevant, since osteoarthritis patients commonly take NSAIDs.
Conclusion and Next Steps
Decision: Hold
Rationale: The osteoarthritis prediction has no clinical trials, and all retrieved literature concerns bone and joint infections, not degenerative osteoarthritis. The high TxGNN score appears to be a knowledge-graph artefact. Daptomycin also carries a known risk of muscle toxicity, and long-term use for a chronic, non-infectious joint disease would be hard to justify. Rheumatoid arthritis is the only prediction with a preclinical mechanistic signal, and it should be treated as a research question.
To proceed, the following is needed:
- Mechanism of action data from DrugBank
- HSA package insert warnings and contraindications, which are required for any safety screening
- Approved-indication text for the Singapore licences
- For rheumatoid arthritis: replication of the animal findings, dose and exposure assessment, and a human-relevant safety evaluation, particularly of muscle toxicity
- Confirmation that route compatibility (injectable only) is acceptable for any chronic joint disease use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.